Publicacións (33) Publicacións de Olalla Maroñas Amigo

2024

  1. Developments in pharmacogenetics, pharmacogenomics, and personalized medicine

    Pharmacological Research, Vol. 200

  2. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies

    Schizophrenia Research, Vol. 268, pp. 293-301

  3. Farmacogenética.

    Medicina interna (Elsevier España), pp. 1284-1291

  4. Role of CYP2D6 and CYP3A4 polymorphisms on aripiprazole and dehydroaripiprazole concentrations in patients undergoing long-acting treatment

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 135

  5. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition

    Schizophrenia Research

  2. Deletion of the CYP2D6 gene as a likely explanation for the serious side effects of the antipsychotic drug pimozide: a case report

    Frontiers in Pharmacology, Vol. 14

  3. Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

    Investigative ophthalmology & visual science, Vol. 64, Núm. 13, pp. 34

2021

  1. Genetic diversity of drug-related genes in native americans of the brazilian amazon

    Pharmacogenomics and Personalized Medicine, Vol. 14, pp. 117-133

  2. Long runs of homozygosity are associated with Alzheimer’s disease

    Translational Psychiatry, Vol. 11, Núm. 1

  3. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics

    Pharmaceutics, Vol. 13, Núm. 7

2020

  1. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 8, pp. 1661-1666

  2. Anti-VEGF treatment and response in age-related macular degeneration: Disease’s susceptibility, pharmacogenetics and pharmacokinetics

    Current Medicinal Chemistry, Vol. 27, Núm. 4, pp. 549-569

  3. Association of BDNF, HTR2A, TPH1, SLC6A4, and comt polymorphisms with tdcs and escitalopram efficacy: Ancillary analysis of a double-blind, placebo-controlled trial

    Brazilian Journal of Psychiatry, Vol. 42, Núm. 2, pp. 128-135

  4. Farmacogenética

    Medicina interna [19ª ed.] (Elsevier España)

  5. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study

    Pharmacotherapy, Vol. 40, Núm. 1, pp. 17-25

  6. The road so far in colorectal cancer pharmacogenomics: Are we closer to individualised treatment?

    Journal of Personalized Medicine, Vol. 10, Núm. 4, pp. 1-40

2019

  1. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

    Alzheimer's and Dementia, Vol. 15, Núm. 10, pp. 1333-1347

  2. Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration

    Pharmaceutics, Vol. 11, Núm. 8

2016

  1. Progress in pharmacogenetics: Consortiums and new strategies

    Drug Metabolism and Personalized Therapy, Vol. 31, Núm. 1, pp. 17-23